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Received July 30, 2012; accepted October 31, 2012AbstractBackground: The glutathione thymidine repeats [(GT)n] of the heme oxygenase (HO)-1 gene promoter have been shown to be correlated with the
incidence of coronary artery disease (CAD), patients with shorter repeats being less likely to have CAD. In this study, we investigated whether
(GT)n repeats in the HO-1 promoter were related to a quantitative angiographic severity of CAD.
Methods: The allele frequency of the HO-1 gene promoter (GT)n repeats was examined in CAD patients with de novo lesions (n ¼ 328).
Patients’ baseline coronary severity was quantified using the Jeopardy scoring system.
Results: The allele frequency of GT repeats in the HO-1 gene promoter had bimodal peaks at (GT)23 and (GT)30. Therefore, we defined allele
classes as follows: S allele (<23 repeats), M allele (23e29 repeats), and L allele (30 repeats). The group with severe CAD (Jeopardy score 8)
had a significantly lower frequency of the S allele (3.7% vs. 8.9%; p ¼ 0.042) than the group with moderate CAD (Jeopardy score <8). None of
the patient with the highest score of 12 (n ¼ 17) carried the class S allele. In a multivariate binary logistic analysis, being a carrier of shorter GT
repeats was a significant negative predictor (odds ratio 0.393; p ¼ 0.024) of a higher Jeopardy score grade of CAD.
Conclusion: Our study showed that shorter (GT)n repeat in the HO-1 gene promoter were associated with a lower Jeopardy severity score in
patients with significant CAD.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Heme oxygenase (HO)-1 is a rate-limiting enzyme for
degrading heme into carbon monoxide, free iron, and* Corresponding author. Dr. Wen-Jane Lee, Department of Medical
Research, Taichung Veterans General Hospital, 160, Section 3, Taichung-Kang
Road, Taichung 407, Taiwan, ROC.
E-mail address: wjlee@vghtc.gov.tw (W.-J. Lee).
1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.03.005biliverdin.1 Carbon monoxide, like nitric oxide, is a potent
vasodilator, and biliverdin and its end-product bilirubin are
antioxidants in vascular cells.1,2 Moreover, HO-1 also pro-
motes angiogenesis and inhibits vascular smooth muscle cell
proliferation.3,4
The number of glutathione thymidine (GT) dinucleotide
repeats in the HO-1 gene promoter regulates gene transcription
activity.5,6 Longer GT repeats in the HO-1 gene promoter have
been reported to be associated with susceptibility to coronaryhinese Medical Association. All rights reserved.
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ischemic stroke,7 an increased incidence of type 2 diabetes
mellitus,8 and a higher restenosis rate after percutaneous
coronary intervention (PCI).9 By contrast, shorter GT repeats
have been shown to be correlated with higher HO-1 promoter
activity in vitro,5 a lower incidence of CAD in a population
with coronary risk factors,10 fewer coronary events in patients
with peripheral artery disease,11 and a lower restenosis rate
after PCI.6 However, some studies have not supported findings
that (GT)n repeats in the HO-1 promoter are related to sus-
ceptibility to CAD12 or restenosis after PCI.13
Several scoring systems have been developed to quantify
the angiographic severity of coronary atherosclerosis and have
been correlated with CAD outcomes.14e17 Among them, the
Jeopardy score offers a simple and precise method for esti-
mating the myocardium at risk and has been shown to corre-
late with long-term survival rates in patients with CAD,14 the
outcomes of cardiogenic shock after myocardial infarction,18
and in-hospital cardiac mortality after acute vessel closure in
PCI.19
To further explore the link between HO-1 promoter (GT)n
repeats and the quantitative angiographic severity of CAD, we
conducted a retrospective analysis of patients who had un-
dergone cardiac catheterization.
2. Methods2.1. Study populationA Windows 2000-based cardiac catheterization report
databank has recently been established in our institute, using
hospital information system data stored in the mainframe; this
contains all of the hospital’s angiographic report data for the
past 15 years. In addition, a serum and buffy coat databank for
all patients who had undergone different types of cardiac
catheterization and who were willing to donate their blood
samples for academic use was established in March 1999. All
study participants gave their informed consent prior to the
blood sampling.
The current study is a substudy of an original protocol that
investigated the association between inflammation-linked
markers and postcoronary intervention restenosis.20,21 During
the study period from March 1999 to January 2004, a total of
11,200 coronary angiogram procedures were undertaken in our
institute’s catheterization laboratories. Among them, 1566 Han
Chinese patients received more than one procedure for various
reasons. Patients who had an acute infection or systemic
inflammation disorders such as connective tissue disease were
also excluded from the study. Those who had a history of
coronary revascularization prior to the first (index) coronary
angiogram in the study period were also excluded, as were
patients who had had severe heart failure, surgery, advanced
renal insufficiency, or cerebrovascular events in the 2 months
prior to the index coronary angiograms.
The database was queried for consecutive patients with
stable angina who had angiographic follow-ups after PCI for
de novo native lesions. Patients who met the catheterizationinclusion criteria (coronary lesions with stenosis of 75% of
the vessel diameter that were associated with objective evi-
dence of ischemia) were subsequently checked in the buffy
coat databank for preprocedural blood samples taken at the
index PCI. The relevant clinical demographic data were
retrieved from the database and completed by thoroughly
reviewing the medical chart records. Because this is a substudy
of “restenosis vs. non-restenosis” after PCI, all the cases were
CAD with de novo lesions that underwent a coronary angio-
gram at least twice and donated buffy coat samples for
leukocyte genomic DNA extraction within the study period
(n ¼ 328). Consequently, potential case selection bias could
not be avoided. The study protocol was approved by the
institutional review board for human research of Taichung
Veterans General Hospital (Taichung, Taiwan).2.2. Jeopardy score and angiographic definitionAngiographic measurements were made on a viewing
workstation with software for the quantitative analysis of an-
giograms (Philips Inturis Suite R2.2; Philips Medical Systems,
Eindhoven, The Netherlands). The Jeopardy scoring system
was designed to estimate the myocardium at risk or in jeop-
ardy.14 The coronary arteries were divided into six major
segments: left anterior descending artery, major diagonal
branch, major septal branch, left circumflex artery, major
obtuse marginal branch, and right coronary artery. Two points
were given to each segment with >75% stenosis, and 2 points
were added to the total score for each vessel that was distal to
a 75% stenosis.14 Therefore all study patients with significant
coronary stenosis could be graded with a quantitative Jeopardy
score (range 2e12) for the severity of their coronary angio-
graphic results.2.3. Definition of conventional risk factors for
atherosclerosisPatients with hypertension were identified as either: (1)
those with a systolic blood pressure over 140 mmHg or a
diastolic pressure over 90 mmHg after multiple measurements
in a sitting position at rest; or (2) patients already taking
antihypertensive medication. Patients with diabetes mellitus
were defined as: (1) those with a fasting blood sugar level over
126 mg/dL on two occasions; or (2) patients already taking
oral antidiabetic agents or insulin injections. Hypercholester-
olemia was defined as: (1) a level of total cholesterol over
200 mg/dL; or (2) a low-density lipoprotein cholesterol (LDL-
C) level over 130 mg/dL at their index baseline admission or
on other traceable past records prior to the use of an HMG-
CoA reductase inhibitor.22,232.4. Analysis of length polymorphism of (GT)n repeats in
the HO-1 gene promoterGenomic DNA was extracted from leukocytes by conven-
tional procedures. The 50-flanking region containing (GT)n re-
peats of the HO-1 gene was amplified by polymerase chain
Table 1





score <8) (n ¼ 220)
Severe CAD (Jeopardy
score 8) (n ¼ 108)
pa
Age (years) 66  10 65  10 68  9 0.022
Gender (M/F) 268/60 178/42 90/18 0.703
Current smoking, n (%) 76 (23%) 48 (22%) 28 (26%) 0.491
Diabetes mellitus, n (%) 123 (38%) 77 (35%) 46 (43%) 0.225
Hypertension, n (%) 229 (70%) 154 (70%) 75 (69%) 1.000
Hypercholesterolemia, n (%) 150 (46%) 94 (43%) 56 (52%) 0.150
Fasting glucose (mg/dL) 128  58 125  53 134  66 0.182
Total cholesterol (mg/dL) 195  46 193  42 197  53 0.520
Triglyceride (mg/dL) 154  109 156  121 149  80 0.587
Medication use
Statin 98 (30%) 65 (30%) 33 (31%) 0.953
Fibrates 16 (5%) 10 (5%) 6 (6%) 0.899
ACEI or ARB 197 (60%) 130 (59%) 67 (62%) 0.695
Fibrates were peroxisome proliferator activator receptor-a agonists. Statins were HMG-CoA reductase inhibitors.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker.
a Patients with moderate versus severe CAD.
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TGCTAAGTTCCTGATGTTGCCCACCAGGCT-30, and an
antisense primer, 50- GCGGAACAGCTGATGCCCACTTT
CTGGCCG-30, according to the published procedure. The PCR
products were mixed together with a GenoType TAMRA DNA
ladder (size range 50e500 bp; Gibco-BRL, Grand Island, NY)
and analyzed with an automated DNA sequencer (ABI Prism
377, Grand Island, NY). The size of each (GT)n repeat was
calculated using GeneScan analysis software (PE Applied
Biosystems, Grand Island, NY). To further confirm the sizes of
the (GT)n repeats, some of the PCR products were subcloned
into a pCRTMII vector (Invitrogen, Grand Island, NY), and the
purified plasmid DNAs were subjected to sequence analysis.2.5. Statistical analysisContinuous variables are expressed as mean  standard de-
viation, and categorical data as percentages. Differences in
continuous variables between groups were assessed by the in-
dependent t test or ManneWhitney U test as appropriate.Table 2
Distribution of the heme oxygenase (HO)-1 gene promoter genotypes in corona
(n ¼ 328).
Genotype,
n (%, in row)
2 (n ¼ 71) 4 (n ¼ 35) 6 (n ¼ 114)
SS 0 0 2 (100%)
SM 4 (15.4%) 4 (15.4%) 11 (42.3%)
SL 7 (41.1%) 1 (5.9%) 8 (47.1%)
MM 9 (18.0%) 14 (28.0%) 12 (24.0%)
ML 35 (22.9%) 11 (7.2%) 53 (34.6%)
LL 16 (20.0%) 5 (6.3%) 8 (35.0%)
L allele ¼ longer GT repeat (30 repeats) in the HO-1 gene promoter; M a
S allele ¼ shorter GT repeat (<23 repeats) in the HO-1 gene promoter.
a Chi-square test.Categorical variables were compared by Chi-square test with
Yate’s correction or Fisher’s exact test. Multivariate binary lo-
gistic regression analysiswas used to test independent predictors
for a higher Jeopardy score (8) in patients with significant
CAD. A two-tailed p value <0.05 was considered statistically
significant. The SPSS 12.1 statistical software package (SPSS
Inc., Chicago, IL, USA) was used for all calculations.
3. Results3.1. Baseline demographic dataA total of 328 patients with significant coronary artery
stenosis were enrolled for analysis. The patients were divided
into two groups: moderate CAD (Jeopardy score <8,
n ¼ 220) or severe CAD (Jeopardy score 8, n ¼ 108).
Baseline demographic data, including atherosclerotic risk
factors, were similar between the two groups except that the
patients in the group with severe CAD were significantly
older (Table 1).ry artery disease patients by Jeopardy score grade for angiographic severity
Jeopardy score
8 (n ¼ 55) 10 (n ¼ 36) 12 (n ¼ 17) p ¼ 0.024a
Total (n ¼ 328)
0 0 0 2
4 (15.4%) 3 (11.5%) 0 26
0 1 (5.9%) 0 17
5 (10.0%) 7 (14.0%) 3 (6.0%) 50
26 (17.0%) 19 (12.4%) 9 (5.9%) 153
0 (25.0%) 6 (7.4%) 5 (6.3%) 80
llele ¼ moderate GT repeat (23e29 repeats) in the HO-1 gene promoter;
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coronary artery disease patients with Jeopardy score-
graded angiographic severityThe atherosclerotic severities of patients with CAD were
graded according to their Jeopardy score (Table 2). The allele
frequency of the GT repeat in the HO-1 gene promoter had
bimodal peaks at (GT)23 and (GT)30; therefore, we defined
allele classes as follows: class S allele (<23 GT repeats), class
M allele (23e29 GT repeats), and class L allele (30 GT
repeats) (Fig. 1A). The distribution of the six genotypes (SS,
SM, SL, MM, ML, and LL) was asymmetric among the CAD
patients with different Jeopardy score-graded (range 2e12)
severities ( p ¼ 0.024) (Table 2). In the group (n ¼ 17) with the
highest severity score (12), none of the patients carried the
class S allele (Table 2).3.3. Carriers of the shorter (GT)n repeat (<23 repeats)
allele in the HO-1 gene promoter versus non-carriers
with moderate or severe coronary atherosclerosisThe group with moderate CAD (Jeopardy score <8) had
more carriers of the class S allele (16.8% vs. 7.4%, p¼0.031)
than the group with severe CAD (Jeopardy score 8). The
odds ratio for carriers of the class S allele with severe CAD
(Jeopardy score 8) was 0.396 (95% confidence interval
0.177e0.882; p ¼ 0.031). In terms of distribution of allele
frequency, the group with severe CAD had a significantly
lower frequency of the class S allele (3.7 % vs. 8.9%;
p ¼ 0.042) than the group with moderate CAD (Table 3,
Fig. 1B and C).3.4. The average (GT)n repeat number of the HO-1 gene
promoter in moderate versus severe coronary
atherosclerosisMoreover, if we assumed a codominant (additive) trait
model for the HO-1 gene promoter and calculated an average
(GT)n repeat number for each patient, the group with severe
CAD (Jeopardy score 8) had a significantly longer average
(GT)n (27.8  3.2 vs. 27.0  3.1; p ¼ 0.041) than the group
with moderate CAD (Jeopardy score <8).Fig. 1. Frequency distribution of (GT)n repeats in the heme oxygenase (HO-1)
gene promoter. (A) All patients with coronary artery disease (CAD; n ¼ 328),
showing a bimodal peak at (GT)23 and (GT)30. (B) Moderate CAD (Jeopardy3.5. Multivariate binary logistic regression analysis of
independent predictors for a higher Jeopardy score in
patients with significant coronary artery stenosisscore <8; n ¼ 220). (C) Severe CAD (Jeopardy score 8; n ¼ 108).
In a multivariate binary logistic regression model with
adjustment for conventional risk factors, including hyperten-
sion, diabetes mellitus, hypercholesterolemia, and gender,
being a carrier of shorter GT repeats was a significant negative
predictor (odds ratio 0.393; p ¼ 0.024) of severe CAD
(Jeopardy score 8) (Table 4). By contrast, age was a positive
predictor (odds ratio 1.031; p ¼ 0.017) of severe CAD
(Jeopardy score 8) (Table 4).4. Discussion
Carriers of the shorter (GT)n repeats in the HO-1 gene
promoter have been shown to have a lower incidence of CAD
in the general population with coronary risk factors.10 How-
ever, no study has provided conclusive evidence that the HO-1
gene promoter (GT)n repeat microsatellite polymorphism
Table 3





score <8) (n ¼ 220)
Severe CAD (Jeopardy
score 8) (n ¼ 108)
pa
S 39 (83.0 %) 8 (17 %) 0.042
M 188 (67.4 %) 91 (32.6 %)
L 213 (64.5 %) 117 (35.5 %)
L allele ¼ longer GT repeat (30 repeats) in the HO-1 gene promoter; M allele ¼ moderate GT repeat (23e29 repeats) in the HO-1 gene promoter; S
allele ¼ shorter GT repeat (<23 repeats) in the HO-1 gene promoter.
a Chi-square test.
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severity. In our study, we found that carriage of shorter (GT)n
repeats in the HO-1 gene promoter was associated with a
lower angiographic severity in patients with significant coro-
nary artery stenosis.
Age is an important risk factor for coronary atheroscle-
rosis.24 Patients in the group with severe CAD were signifi-
cantly older than those in the group with moderate CAD in this
study (Table 1). However, after adjusting for age and other
conventional risk factors for coronary atherosclerosis, carriage
of shorter (GT)n repeats (the class S allele) in the HO-1 gene
promoter remained a significant negative predictor for a higher
Jeopardy score-graded severity of coronary atherosclerosis
(Table 4).
Induction of HO-1 in vascular endothelial cells and smooth
muscle cells by proatherogenic agents such as oxidized LDL-
C, hypoxia, and proinflammatory cytokines could provide a
secondary line of antioxidant defense and maintain vessel
patency through the generation of carbon monoxide.25e28 The
HO-1 promoter and its transcriptional activity are regulated by
multiple insults, transcription factors, and their response ele-
ments.26 Patients with coronary atherosclerosis usually mani-
fest a status of higher oxidative stress that has induced the HO-
1 expression.26,29 The (GT)n repeat polymorphism of the HO-1
gene promoter was one of the genetic factors that determined
its transcription in patients with CAD.
Previous in vitro studies have revealed that shorter (GT)n
repeats in the HO-1 gene promoter were associated with
higher transcriptional activity.5 Carriers of shorter (GT)n re-
peats in the HO-1 gene promoter had a lower incidence of
CAD in a population with coronary risk factors.10 The aboveTable 4
Multivariate binary logistic regression analysis of independent predictors for a hig
stenosis (n ¼ 328).
Factors p
Age (years) 0.017
Hypertension (with vs. without) 0.893
Diabetes mellitus (with vs. without) 0.190
Hypercholesterolemia (with vs. without) 0.074
Gender (male vs. female) 0.664
Carriers of class S allele (carriers vs. non-carriers) 0.024
Dependent variable: Severe coronary artery disease (Jeopardy severity score 8).
Class S allele ¼ shorter (GT)n repeat (<23 repeats) in the heme oxygenase-1 genfindings may imply that a higher transcription of the HO-1
gene provides protection against atherosclerosis.
By contrast, some studies have indicated that HO-1 protein
expression was higher in complex or high-grade stenotic
coronary lesions or in the coronary arteries of diabetic in-
dividuals.30 Morsi et al demonstrated that HO-1 expression
and activity in endothelial cells were only present in advanced
atherosclerosis but not in healthy controls.31 Moreover, Chen
et al reported that there was higher HO-1 protein expression in
the peripheral leukocytes of patients with CAD than in healthy
controls,32 patients with acute myocardial infarction showing
the highest expression.33 In addition, Idriss et al reported the
presence of a secretory form of HO-1 protein in plasma whose
concentration was highest in acute coronary syndrome, fol-
lowed by stable CAD, with healthy controls having the lowest
concentration of secretory HO-1.34
These studies on increased HO-1 expression and activity in
advanced atherosclerosis increase the controversy over
whether HO-1 itself could protect against atherosclerosis or
just serve as a post hoc defense against disease progression.
We postulated that a higher expression of HO-1 protein was an
adaptation and adjustment to overcome the higher oxidative
stress and acted as a promoter of angiogenesis in established
and advanced CAD. However, a shorter (GT)n repeat in the
HO-1 gene promoter still could provide a background genetic
protection against atherosclerosis.
There are two major limitations to our study. First, we did
not have HO-1 protein expression data for plasma, peripheral
leukocytes, or coronary tissues to document the association
between the HO-1 promoter microsatellite polymorphisms and
actual protein expression. Second, we did not have long-termher Jeopardy severity score (8) in patients with significant coronary artery
Odds ratio 95% Confidence interval
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event rates to link this HO-1 gene promoter polymorphism to
cardiovascular outcomes.
In conclusion, our study showed that carriage of shorter GT
repeats in the HO-1 gene promoter was associated with a
lower Jeopardy severity score in patients with significant
coronary artery stenosis.Acknowledgments
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